196 related articles for article (PubMed ID: 34134639)
41. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
Spivak JL
Ann Intern Med; 2010 Mar; 152(5):300-6. PubMed ID: 20194236
[TBL] [Abstract][Full Text] [Related]
42. Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique.
Leszczynska A; Grzenkowicz-Wydra J; Chmielewska-Gorycka L; Bieniaszewska M; Hellmann A
Acta Haematol; 2016; 136(2):123-8. PubMed ID: 27410038
[TBL] [Abstract][Full Text] [Related]
43. Direct intrahepatic portocaval shunt for treatment of portal thrombosis and Budd-Chiari syndrome.
Pedersen MR; Molloy P; Wood D; Seetharam A
Ann Hepatol; 2016; 15(1):127-30. PubMed ID: 26626649
[TBL] [Abstract][Full Text] [Related]
44. Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.
Basquiera AL; Tabares AH; Soria N; Salguero M; Ryser R; García JJ
Medicina (B Aires); 2011; 71(4):313-6. PubMed ID: 21893442
[TBL] [Abstract][Full Text] [Related]
45. Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Landolfi R; Di Gennaro L
Haematologica; 2008 Mar; 93(3):331-5. PubMed ID: 18310537
[No Abstract] [Full Text] [Related]
46. [Polycythemia vera and JAK-2 mutation in childhood: a case report].
Braconnier O; Monpoux F; Affanetti M; Bérard E; Sirvent N
Arch Pediatr; 2007 Oct; 14(10):1202-5. PubMed ID: 17693067
[TBL] [Abstract][Full Text] [Related]
47. Co-occurrence of JAK2 V617F and an uncommon CALR del (p.K368fs*51) mutation facilitates JAK2/STAT signaling in polycythemia vera.
Xing CY; Li HY; Wu JB; Gao SM
Leuk Lymphoma; 2016 Jul; 57(7):1743-5. PubMed ID: 26701108
[No Abstract] [Full Text] [Related]
48. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
49. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
50. Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation.
Bernardi M; Ruggeri M; Albiero E; Madeo D; Rodeghiero F
Am J Hematol; 2009 Apr; 84(4):258-60. PubMed ID: 19229983
[No Abstract] [Full Text] [Related]
51. Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Gadisseur A; Lam KH; De Raeve H; Schroyens W
Acta Haematol; 2015; 133(1):56-63. PubMed ID: 25116182
[TBL] [Abstract][Full Text] [Related]
52. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
53. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
54. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
Passamonti F; Elena C; Schnittger S; Skoda RC; Green AR; Girodon F; Kiladjian JJ; McMullin MF; Ruggeri M; Besses C; Vannucchi AM; Lippert E; Gisslinger H; Rumi E; Lehmann T; Ortmann CA; Pietra D; Pascutto C; Haferlach T; Cazzola M
Blood; 2011 Mar; 117(10):2813-6. PubMed ID: 21224469
[TBL] [Abstract][Full Text] [Related]
55. A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2
Pang Y; Gupta G; Yang C; Wang H; Huynh TT; Abdullaev Z; Pack SD; Percy MJ; Lappin TRJ; Zhuang Z; Pacak K
BMC Cancer; 2018 Mar; 18(1):286. PubMed ID: 29534684
[TBL] [Abstract][Full Text] [Related]
56. New and old prognostic factors in polycythemia vera.
Passamonti F
Curr Hematol Malig Rep; 2009 Jan; 4(1):19-24. PubMed ID: 20425434
[TBL] [Abstract][Full Text] [Related]
57. Vertebral artery thrombosis: a rare presentation of primary polycythaemia.
Gul HL; Lau SY; Chan-Lam D; Ng JP
BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24862411
[TBL] [Abstract][Full Text] [Related]
58. Aquagenic pruritus and the JAK2 V617F mutation.
Langabeer SE
Clin Exp Dermatol; 2019 Apr; 44(3):e33. PubMed ID: 30578575
[No Abstract] [Full Text] [Related]
59. Chorea in the elderly with mutation positive polycythemia vera: a case report.
Kumar H; Masiowski P; Jog M
Can J Neurol Sci; 2009 May; 36(3):370-2. PubMed ID: 19534341
[No Abstract] [Full Text] [Related]
60. Molecular evidence of JAK2 p.V617F mutated pure erythroid leukemia arising from polycythemia vera.
Ware AD; Birkness J; Duffield AS; Gocke CD
Virchows Arch; 2018 Jul; 473(1):131-135. PubMed ID: 29611054
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
